ES2194935T3 - Preparados estables de transglutaminasa y procedimiento para su preparacion. - Google Patents

Preparados estables de transglutaminasa y procedimiento para su preparacion.

Info

Publication number
ES2194935T3
ES2194935T3 ES96101959T ES96101959T ES2194935T3 ES 2194935 T3 ES2194935 T3 ES 2194935T3 ES 96101959 T ES96101959 T ES 96101959T ES 96101959 T ES96101959 T ES 96101959T ES 2194935 T3 ES2194935 T3 ES 2194935T3
Authority
ES
Spain
Prior art keywords
transglutaminase
procedure
preparation
stable preparations
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96101959T
Other languages
English (en)
Inventor
Hubert Dr Metzner
Hermann Dr Karges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH
Original Assignee
Aventis Behring GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Behring GmbH filed Critical Aventis Behring GmbH
Application granted granted Critical
Publication of ES2194935T3 publication Critical patent/ES2194935T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE FORMAS ESTABLES DE UNA COMPOSICION DE TRANSGLUTAMINASA, POR EJEMPLO EL FACTOR XIII, QUE DESPUES DE LA LIOFILIZACION ES SOLUBLE Y SIN TURBIEDAD Y CONTIENEN LA TRANSGLUTAMINASA PURIFICADA ASI COMO LOS D- Y/O LAMINOACIDOS, EXCEPTO GLICINA Y ARGININA, SUS SALES, DERIVADOS Y HOMOLOGOS, DIMEROS U OLIGOMEROS DE ELLOS, O MEZCLAS DE ELLOS, Y/O AZUCAR O ALCOHOLES DEL AZUCAR, OPCIONALMENTE EN COMBINACION CON TENSIOACTIVOS Y/O REDUCTORES. LA INVENCION TRATA ADEMAS DE UN PROCEDIMIENTO PARA LA OBTENCION DE PREPARACIONES ESTABLES DE PROTEINA, Y LA UTILIZACION DE LAS FORMAS ESTABLES DESCRITAS PARA OBTENER MEDICAMENTOS, QUE POR EJEMPLO SON APROPIADOS PARA EL TRATAMIENTO DE ENFERMEDADES CARACTERIZADAS POR LA CARENCIA DEL F XIII.
ES96101959T 1995-03-09 1996-02-10 Preparados estables de transglutaminasa y procedimiento para su preparacion. Expired - Lifetime ES2194935T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19508192A DE19508192A1 (de) 1995-03-09 1995-03-09 Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ES2194935T3 true ES2194935T3 (es) 2003-12-01

Family

ID=7756017

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96101959T Expired - Lifetime ES2194935T3 (es) 1995-03-09 1996-02-10 Preparados estables de transglutaminasa y procedimiento para su preparacion.

Country Status (13)

Country Link
US (1) US6204036B1 (es)
EP (1) EP0733702B1 (es)
JP (1) JP3530300B2 (es)
KR (1) KR100457485B1 (es)
CN (1) CN1149283C (es)
AT (1) ATE239783T1 (es)
AU (1) AU4791596A (es)
CA (1) CA2171266C (es)
DE (2) DE19508192A1 (es)
ES (1) ES2194935T3 (es)
IL (1) IL117405A (es)
NO (1) NO319174B1 (es)
NZ (1) NZ286046A (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3651003B2 (ja) * 1994-10-11 2005-05-25 味の素株式会社 安定化されたトランスグルタミナーゼ及びそれを含む酵素製剤
JPH08333277A (ja) * 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
CA2280130C (en) * 1997-02-05 2007-12-18 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing sphingoglycolipid and process for preparing them
JP4524076B2 (ja) * 2003-04-02 2010-08-11 天野エンザイム株式会社 安定化トランスグルタミナーゼ
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
ATE378349T1 (de) * 2004-06-25 2007-11-15 Kuehni Ag Verfahren zur extraktion von biologischem material
JP5139275B2 (ja) * 2005-06-21 2013-02-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｒ）−（−）−２−［５−（４−フルオロフェニル）−３−ピリジルメチルアミノメチル］クロマンを含有する固体医薬組成物
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
DE102006033167A1 (de) * 2006-07-10 2008-01-24 Gelita Ag Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung eines vernetzenden medizinischen Klebers
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
JP2010529850A (ja) * 2007-06-16 2010-09-02 エニグマ ディアグノスティックス リミテッド 組成物
KR101699554B1 (ko) * 2007-08-15 2017-01-25 서카시아 리미티드 백신용 펩티드
PL2268267T3 (pl) * 2008-04-21 2017-12-29 Novo Nordisk Health Care Ag Kompozycja sucha transglutaminazy
AU2015227499B2 (en) * 2008-11-28 2017-06-22 Circassia Limited Compositions with reduced dimer formation
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US20100316764A1 (en) * 2009-06-10 2010-12-16 Engrain, LLC Flour supplement compositions and methods for preparing wheat flour
CN101995459A (zh) * 2009-08-26 2011-03-30 刘萍 包被板封闭液
JP2013532649A (ja) * 2010-07-22 2013-08-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 初期免疫防御において新規な機能を発揮する先祖セリンプロテアーゼ凝固カスケード
CN102533689A (zh) * 2011-12-30 2012-07-04 华东师范大学 一种谷氨酰胺转胺酶真空干燥的制备方法
CN104274827B (zh) * 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
CN104198422B (zh) * 2014-08-18 2017-04-19 苏州康铭诚业医用科技有限公司 一种用于α‑羟丁酸脱氢酶测定试剂盒的复合稳定剂
CN104388531B (zh) * 2014-10-20 2017-01-18 苏州康铭诚业医用科技有限公司 一种用于乳酸脱氢酶试剂盒的复合稳定剂
CN105018457A (zh) * 2015-07-20 2015-11-04 宁波美成生物科技有限公司 虫荧光素酶稳定剂
JP2017110001A (ja) * 2015-12-16 2017-06-22 株式会社 資生堂 タブレット型凍結乾燥化粧料
CN105543204A (zh) * 2015-12-30 2016-05-04 海口奇力制药股份有限公司 一种组合物及其应用、含有该组合物的稳定剂
CN107177567B (zh) * 2016-02-16 2018-07-03 上海青瑞食品科技有限公司 一种液体酶制剂及制备方法
RU2744630C2 (ru) 2016-09-16 2021-03-12 Льюкокэар Аг Новый способ стабилизации биофармацевтического лекарственного продукта при производстве

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2063070C3 (de) 1970-12-22 1975-07-24 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung
JPS5359018A (en) 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JPH03240738A (ja) * 1990-02-20 1991-10-28 Hoechst Japan Ltd 糖尿病性壊疽治療剤
FR2664165B1 (fr) * 1990-07-03 1992-10-16 Lille Transfusion Sanguine Composition pour stabiliser le plasma sanguin en cours de pasteurisation.
WO1993003147A1 (en) 1991-08-07 1993-02-18 Zymogenetics, Inc. Purification of factor xiii
NZ246865A (en) * 1992-01-22 1996-10-28 Novo Nordisk As Activated factor xiii (plasma transglutaminase) and its use in food products and compositions
JP3353383B2 (ja) * 1992-06-02 2002-12-03 味の素株式会社 酵素製剤及び結着成形食品の製造法
EP0572987B1 (en) * 1992-06-02 1999-08-25 Ajinomoto Co., Inc. Process for producing bound-formed food
AT402788B (de) * 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation

Also Published As

Publication number Publication date
EP0733702A1 (de) 1996-09-25
JPH08245418A (ja) 1996-09-24
CA2171266C (en) 2010-05-18
KR960034408A (ko) 1996-10-22
NO960813L (no) 1996-09-10
CN1137564A (zh) 1996-12-11
IL117405A (en) 2002-05-23
NO960813D0 (no) 1996-02-28
ATE239783T1 (de) 2003-05-15
DE59610414D1 (de) 2003-06-12
JP3530300B2 (ja) 2004-05-24
NO319174B1 (no) 2005-06-27
IL117405A0 (en) 1996-07-23
US6204036B1 (en) 2001-03-20
NZ286046A (en) 1997-09-22
CA2171266A1 (en) 1996-09-10
EP0733702B1 (de) 2003-05-07
DE19508192A1 (de) 1996-09-12
CN1149283C (zh) 2004-05-12
AU4791596A (en) 1996-09-19
KR100457485B1 (ko) 2005-02-02

Similar Documents

Publication Publication Date Title
ES2194935T3 (es) Preparados estables de transglutaminasa y procedimiento para su preparacion.
MX9201298A (es) Nuevos conjugados de proteinas con poli etilen glicol, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ATE433663T1 (de) Neue konservierungssysteme und deren verwendung in kosmetischen mitteln
ES2217253T3 (es) Tioesterasas vegetales de cadena media.
PT1017413E (pt) Formulacoes liquidas de interferao (beta)
BR9806911A (pt) Processos para hidrólise seletiva de caseina/caseinato, para preparar uma preparação de proteìna de leite hidrolisada, para preparar um hidrolisado de proteìna de leite, e para preparar uma preparação de proteìna que possui um nìvel de caseìna reduzido, uso de uma proteinase especìfica para caseìna/caseinato, hidrolisado de proteìna de leite, uso do mesmo, preparação de proteìna de leite esgotada de caseìna, e, uso da mesma.
EE9500015A (et) Meetod pranoprofeeni stabiliseerimiseks ja pranoprofeeni stabiilne vedelpreparaat
Blondin et al. Measures of leucine aminopeptidase can be used to anticipate UV-induced age-related damage to lens proteins: ascorbate can delay this damage
ES2097120T3 (es) Estabilizacion de proteinas altamente purificadas.
BR9910399A (pt) Novos intermediários e processos para a preparação de derivados de ácido octanóico opticamente ativo
MX5721A (es) Sales de 5'-metiltio-5'-deoxiadenosina con acidos sulfonicos de cadena larga y procedimiento para su preparacion.
DE69416764T2 (de) Verfahren zur Stabilisierung eines Kontaktlinsenpräparats
EP0674001A2 (en) Novel protease for treating devitalized tissue
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
ES2046552T3 (es) Procedimiento para la fabricacion de hidrolizados de proteinas con bajo contenido de sustancias amargantes.
EA199901117A1 (ru) Модуляторы путей внутриклеточного воспаления, клеточной гибели и клеточного выживания
BR9002240A (pt) Processo para a preparacao de uma composicao conservada apropriada para aplicacao topica a pele e composicao
CO4600680A1 (es) Procedimientos para la prevencion de la degradacion de la proteina c
Matsumoto et al. Physical properties of glutamate decarboxylase from squash
BR9004693A (pt) Solucao aquosa,processo para aumentar a concentracao de proteina de uma proteina em uma solucao aquosa,e composicao farmaceutica
ES2062033T3 (es) Preparaciones de acido-ureasa para bebidas alcoholicas.
ES2178639T3 (es) Solucion estable de aminoacidos altamente concentrada.
ES2145259T3 (es) Procedimiento de obtencion de productos peptidicos.
DE59301413D1 (de) Verfahren zur Herstellung von Natriumsalzen nitrogruppenhaltiger aromatischer Sulfinsäuren
RU95104309A (ru) Коллагеназа